Financial Performance
As of and for the year ended December 31,
Three-Year Summary
THE CEO
LETTER
From Our CEO
Performance(PDF)
Three-Year Summary
% CHANGE
| Millions (except per common share data) | 2011(a) | 2010 | 2009(a) | 11/10 10/09 |
|---|---|---|---|---|
| Revenues | $ 67,425 | $ 67,057 | $ 49,269 | 1 36 |
| Research and development expenses | $ 9,112 | $ 9,392 | $ 7,824 | (3) 20 |
| Acquisition-related in-process research and development charges | — | $ 125 | $ 68 | (100) 84 |
| Restructuring charges and certain acquisition-related costs | $ 2,934 | $ 3,201 | $ 4,330 | (8) (26) |
| Income from continuing operations | $ 8,739 | $ 8,211 | $ 8,529 | 6 (4) |
| Net income attributable to Pfizer Inc. | $ 10,009 | $ 8,257 | $ 8,635 | 21 (4) |
| Diluted earnings per common share attributable to Pfizer Inc. shareholders | $ 1.27 | $ 1.02 | $ 1.23 | 25 (17) |
| Weighted-average shares—diluted | 7,870 | 8,074 | 7,045 | (3) 15 |
| Number of common shares outstanding | 7,575 | 8,012 | 8,051 | (5) — |
| Working capital | $ 29,659 | $ 32,377 | $ 24,929 | (8) 30 |
|
Goodwill & other identifiable intangible assets, net |
$ 98,900 | $ 101,483 | $ 110,372 | (3) (8) |
| Total assets | $ 188,002 | $ 195,014 | $ 212,949 | (4) (8) |
| Total debt(b) | $ 38,949 | $ 44,013 | $ 48,637 | (12) (10) |
| Total Pfizer Inc. shareholders' equity | $ 82,190 | $ 87,813 | $ 90,014 | (6) (2) |
| Shareholders' equity per common share | $ 10.85 | $ 10.96 | $ 11.19 | (1) (2) |
| Net cash provided by operating activities | $ 20,240 | $ 11,454 | $ 16,587 | 77 (31) |
| Property, plant and equipment additions | $ 1,660 | $ 1,513 | $ 1,205 | 10 26 |
| Purchases of common stock | $ 9,000 | $ 1,000 | — | * 100 |
| Cash dividends paid | $ 6,234 | $ 6,088 | $ 5,548 | 2 10 |
(a) For 2011, includes King Pharmaceuticals Inc. commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.
(b) Our short-term borrowings are rated P-1 by Moody's Investors Service (Moody's) and A1+ by Standard & Poor's (S&P). Our long-term debt is rated A1 by Moody's and AA by S&P. Moody's and S&P are major corporate debt-rating organizations.
* Calculation not meaningful.
Detailed information on our financial and operational performance can be found in the 2011 Financial Report.